Stockreport

Codiak Presents Preclinical Data on exoASO™-STAT6 and exoASO™-C/EBPß Programs at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Codiak BioSciences, Inc.  (CDAK) 
PDF – exoASO-STAT6 demonstrated durable pharmacokinetic/pharmacodynamic profile in preclinical models; biomarkers with clinical translational potential identified, providing [Read more]